Please provide your email address to receive an email when new articles are posted on . Selexipag improved pulmonary vascular resistance and other hemodynamic variables among patients with chronic ...

Sotatercept significantly reduces pulmonary vascular resistance in patients with CpcPH–HFpEF compared with placebo, according to a trial.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among adults with pulmonary arterial hypertension, ...

In adults with Fontan circulation, a higher pulmonary vascular resistance index (PVRI) during exercise and failure to reduce the PVRI were associated with a greater risk for death or heart ...

BARCELONA, Spain—New guidelines for the diagnosis and treatment of pulmonary hypertension (PH), released at the recent European Society of Cardiology (ESC) Congress 2022, include a new hemodynamic ...

Pulmonary arterial hypertension is a progressive disease involving proliferative remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated morbidity and mortality ...

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention. A new paper has highlighted the significant impact of type 2 ...

New findings reveal sotatercept's significant benefits for right ventricular function and tricuspid regurgitation in pulmonary arterial hypertension. At this year’s European Society of Cardiology (ESC ...